The latest announcement is out from Uniphar PLC ( (GB:UPR) ).
Uniphar PLC reported strong financial performance for the year ending December 2024, with an 8% growth in organic gross profit and a 12% increase in adjusted EPS. The company maintains a robust liquidity position with a net debt/EBITDA ratio of 1.5x. Looking ahead, Uniphar expects continued organic growth across all divisions in 2025 and aims to reach a medium-term EBITDA target of €200m, primarily through organic means. The company’s strategic focus on disciplined capital allocation and maintaining an active M&A pipeline underpins its growth strategy.
More about Uniphar PLC
Uniphar PLC is an international diversified healthcare services business. The company operates in the healthcare industry, providing services through its divisions: Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. Uniphar focuses on achieving growth through organic profit increase and strategic mergers and acquisitions.
YTD Price Performance: 4.09%
Average Trading Volume: 24,116
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £480.7M
See more insights into UPR stock on TipRanks’ Stock Analysis page.